section name header

Information

[Section Outline]

Definition !!navigator!!

May occur together or separately. Urticaria involves only the superficial dermis and presents as pruritic, circumscribed wheals with raised serpiginous borders and blanched centers. Angioedema involves deeper layers of skin and may include subcutaneous tissue; it is marked by dramatic swelling with more pain than pruritus. Recurrent episodes of urticaria and/or angioedema of <6 weeks duration are considered acute, whereas attacks persisting beyond this period are chronic.

Classification, Etiology, and Pathophysiology !!navigator!!

The classification of urticaria-angioedema focuses on mechanisms that elicit clinical disease and can be useful for differential diagnosis (Table 159-1 Classification of Urticaria and/or Angioedema). Acute urticaria is most often the result of exposure to a food, environmental or drug allergen or viral infection. Chronic urticaria is often idiopathic with additional etiologies including physical stimuli. Up to 45% of pts with chronic urticaria have an autoimmune cause including autoantibodies to IgE or to the α chain of FcεRI. Hereditary angioedema (HAE) is a fully penetrant, autosomal dominant disease due to a mutation in the SERPING1 gene leading to a deficiency of C1 inhibitor (C1INH) (type 1-85% of pts) or to a dysfunctional protein (type 2).

Diagnosis !!navigator!!

History, with special attention to possible offending exposures and/or ingestion as well as the duration of lesions. Urticarial eruptions appear in crops of 12- to 36-h duration, with old lesions fading as new ones appear. In physical urticarias, individual lesions usually last <2 h. Lesions that last >36 h, result in scarring, and are painful rather than pruritic warrant skin biopsy for urticarial vasculitis. The most common sites for angioedema are periorbital and perioral; upper respiratory tract angioedema may be life-threatening. HAE is suggested by family history, lack of pruritus or urticarial lesions, GI involvement with attacks of colic, and episodes of laryngeal edema.

  • Skin testing to food and/or inhalant antigens
  • Direct reproduction of the lesion in physical urticaria
  • Laboratory examination: CBC with differential (eosinophilia), TSH, erythrocyte sedimentation rate (ESR) are recommended. C1INH and complement levels if HAE is suggested. Expanded testing should be guided by history: assay for serum allergen-specific IgE, mast cell studies, cryoglobulins, hepatitis testing, autoantibody screen.
  • Skin biopsy may be necessary.

Differential Diagnosis !!navigator!!

Atopic dermatitis, contact sensitivity, cutaneous mastocytosis (urticaria pigmentosa), systemic mastocytosis.

Prevention !!navigator!!

Identification and avoidance of offending agent(s), if possible.

TREATMENT

Urticaria and Angioedema

  • H1 antihistamines: e.g., chlorpheniramine, diphenhydramine; or the low or nonsedating agents, e.g., loratadine, desloratadine, fexofenadine, cetirizine, levocetirizine.
  • H2 antihistamines: e.g., ranitidine, famotidine, cimetidine.
  • Older agents with antihistamine properties: doxepin, cyproheptadine, hydroxyzine when H1 agents are inadequate.
  • CysLT1 receptor antagonists can be add-on therapy: e.g., montelukast 10 mg daily or zafirlukast 20 mg bid.
  • Monoclonal anti-IgE antibodies (Omalizumab): for chronic urticaria that has failed long-acting H1 antihistamines QID and a CysLT1 receptor antagonist.
  • Topical glucocorticoids are of no value in the management of urticaria and/or angioedema.
  • Systemic glucocorticoids should not be used in the treatment of idiopathic, allergen-induced, or physical urticaria because of their long-term toxicity. Can be considered with urticarial vasculitis, idiopathic angioedema with or without urticaria, or unresponsive debilitating chronic urticaria.
  • Infusion of isolated or recombinant C1INH protein is approved for prophylaxis of and acute attacks of HAE; a bradykinin 2 receptor antagonist (Icatibant) or a kallikrein inhibitor (Ecallantide) may be used for acute HAE.

Outline

Section 12. Allergy, Clinical Immunology, and Rheumatology